Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells - Archive ouverte HAL Access content directly
Journal Articles EMBO Reports Year : 2019

Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells

(1, 2) , (1) , (1) , (3) , (1) , (1) , (1) , (4, 5) , (4, 5) , (3, 6) , (1, 6) , (1, 6)
1
2
3
4
5
6

Abstract

The effect of anti-HIV-1 antibodies on complement activation at the surface of infected cells remains partly understood. Here, we show that a subset of anti-Envelope (Env) broadly neutralizing antibodies (bNAbs), targeting the CD4 binding site and the V3 loop, triggers C3 deposition and complement-dependent cytotoxicity (CDC) on Raji cells engineered to express high surface levels of HIV-1 Env. Primary CD4 T cells infected with laboratory-adapted or primary HIV-1 strains and treated with bNAbs are susceptible to C3 deposition but not to rapid CDC. The cellular protein CD59 and viral proteins Vpu and Nef protect infected cells from CDC mediated by bNAbs or by polyclonal IgGs from HIV-positive individuals. However, complement deposition accelerates the disappearance of infected cells within a few days of culture. Altogether, our results uncover the contribution of complement to the antiviral activity of anti-HIV-1 bNAbs.
Fichier principal
Vignette du fichier
embr.201949351-3.pdf (2.55 Mo) Télécharger le fichier
Origin : Explicit agreement for this submission

Dates and versions

pasteur-03239697 , version 1 (27-05-2021)

Licence

Copyright

Identifiers

Cite

Jérémy Dufloo, Florence Guivel-Benhassine, Julian Buchrieser, Valérie Lorin, Ludivine Grzelak, et al.. Anti‐ HIV ‐1 antibodies trigger non‐lytic complement deposition on infected cells. EMBO Reports, 2019, 21 (2), pp.e49351. ⟨10.15252/embr.201949351⟩. ⟨pasteur-03239697⟩
23 View
131 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More